COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ meta analysis
10/1 PrEP, PEP
Garcia-Albeniz et al., medRxiv, doi:10.1101/2020.09.29.20203869 (Preprint) (meta analysis - not included in study count)
Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19
Source   PDF   Share   Tweet
Combination of the four underpowered prophylaxis RCTs to date showing statistically significant results, RR 0.78 [0.61-0.99].
The actual effect of HCQ is likely to be higher for several reasons: the trials did not adjust for losses to follow-up or other deviations from protocol. There was very long treatment delays in the postexposure prophylaxis trials - in one trial, about a third of participants were enrolled 4 days after exposure with an additional shipping delay of ~46 hours on average, in the other, participants were enrolled up to 7 days after exposure, with an unknown additional delay before treatment, and results suggesting that exposure detection was delayed.
For other reasons see: [1, 2, 3, 4].

Garcia-Albeniz et al., 10/1/2020, preprint, 5 authors.
risk of COVID-19 case, 22.0% lower, RR 0.78, p = 0.04.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 258 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit